FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation
Kaskela Law LLC has initiated an investigation into Fate Therapeutics, Inc. (NASDAQ: FATE) on behalf of long-term investors following an amended securities fraud complaint. The complaint alleges that Fate made false statements regarding its collaboration with Janssen Pharmaceuticals, which was later terminated, causing Fate's stock to drop over 61% in one day. The firm is seeking to determine if Fate's board breached fiduciary duties and encourages affected shareholders to contact them.
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
The report "IPSC-derived NK Cells Pipeline Insight 2026" from DelveInsight covers clinical developments in iPSC-derived NK cell therapies, highlighting over 12 companies and 15 pipeline drugs. Key players like Century Therapeutics and Fate Therapeutics are advancing treatments for autoimmune disorders, lymphomas, and other cancers. The report emphasizes the potential of iPSC-derived NK cells as a scalable, off-the-shelf option for next-generation cancer immunotherapies.
Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving Average - What's Next?
Fate Therapeutics (NASDAQ:FATE) shares recently crossed above their 50-day moving average, trading at $1.12 with significant volume. The company, which develops cellular immunotherapies, slightly surpassed its quarterly earnings and revenue expectations but remains unprofitable. Analyst consensus on the stock is "Hold" with an average target price of $3.92, while institutional investors maintain a substantial ownership of 97.54%.
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts
Nine analysts have issued a consensus "Hold" rating for Fate Therapeutics, Inc. (NASDAQ:FATE), with an average 12-month price target of $3.92. The biopharmaceutical company's shares are trading at $1.19 with a market cap of $137.3 million, and it reported negative earnings with a P/E ratio of -0.90. Institutional investors hold approximately 97.54% of the stock.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced new employee inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4). A newly-hired non-executive employee received non-qualified stock options for 120,000 shares and restricted stock units for 90,000 shares. These grants, approved by the Compensation Committee, are designed to vest over four years, contingent on continuous employment.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. (NASDAQ: FATE) announced that it granted inducement awards to a newly-hired non-executive employee on February 1, 2026. The awards include non-qualified stock options for 120,000 shares and restricted stock units (RSUs) representing 90,000 shares, as approved by the Compensation Committee. These grants are part of the Company's Amended and Restated Inducement Equity Plan and comply with Nasdaq Listing Rule 5635(c)(4).
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced the granting of inducement awards to a newly-hired non-executive employee on February 1, 2026. These awards include non-qualified stock options for 120,000 shares and restricted stock units for 90,000 shares, approved under Nasdaq Listing Rule 5635(c)(4). The grants are part of the Company’s strategy to attract new talent and will vest over four years, subject to continuous employment.
The Truth About Fate Therapeutics Inc: Is This Biotech Underdog About To Explode Or Implode?
The article discusses the speculative nature of Fate Therapeutics Inc (FATE), a biotech company developing off-the-shelf cell therapies for cancer and immune disorders. It highlights the company's high risk-reward profile, significant stock volatility, and ongoing need for funding, cautioning potential investors to conduct thorough research beyond viral social media trends. The author concludes that FATE is a "speculative cop" only for investors who are prepared for substantial risk, volatility, and extensive research into clinical data and SEC filings.
Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving Average - Here's What Happened
Fate Therapeutics (NASDAQ:FATE) stock crossed above its 50-day moving average on Monday, trading as high as $1.2150. The clinical-stage biopharmaceutical company has a market cap of $137.3 million and a consensus analyst rating of "Hold" with a target price of $3.92. Recent analyst activity shows a mix of downgrades, upgrades, and reiterations, reflecting varied opinions on the stock.
Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 6.3% over the previous year
Institutional investors own 63% of Fate Therapeutics, Inc., a significant stake that makes the stock price sensitive to their trading actions. Despite a 6.3% loss over the past year, these investors likely appreciate the recent US$16 million market cap gain. The top 10 shareholders hold 51% of the company, and hedge funds account for 11% ownership, while insiders own a relatively small US$1.8 million worth of stock and have been selling recently.
Insider Selling: Fate Therapeutics (NASDAQ:FATE) Insider Sells 10,589 Shares of Stock
Fate Therapeutics (NASDAQ:FATE) director Cindy Tahl recently sold 10,589 shares of the company's stock for approximately $11,224, reducing her total holdings to 387,081 shares. The biopharmaceutical company's shares are currently trading around $1.07, and it holds a market capitalization of $123.4 million. Analysts provide a mixed outlook with a consensus "Hold" rating and an average price target of $3.92, while institutional investors own about 97.5% of the stock.
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of "Hold" from Brokerages
Fate Therapeutics (NASDAQ:FATE) has received a consensus "Hold" rating from nine brokerages, with an average one-year target price of $3.92. Despite a negative P/E ratio and profitability metrics, the company recently reported earnings that slightly beat analyst expectations. Institutional ownership is notably high at 97.54%, with several major investors recently increasing their stakes.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced the granting of inducement awards to new non-executive employees under Nasdaq Listing Rule 5635(c)(4). These awards included non-qualified stock options to one employee to purchase 48,000 shares and restricted stock units representing 79,400 shares to four employees, all vesting over four years. These grants are part of the company's strategy to attract talent in its clinical-stage biopharmaceutical operations.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced new employee inducement awards on January 1, 2026, consisting of non-qualified stock options for one employee to purchase 48,000 shares and restricted stock units (RSUs) representing 79,400 shares for four employees. These grants were approved by the Compensation Committee as an inducement for new employment under Nasdaq Listing Rule 5635(c)(4). The options and RSUs will vest over four years, subject to continuous employment.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced new employee inducement awards under Nasdaq Listing Rule 5635(c)(4) on January 5, 2026. These awards, granted on January 1, 2026, include non-qualified stock options for 48,000 shares to one new non-executive employee and restricted stock units (RSUs) for 79,400 shares to four new non-executive employees. The grants were approved by the Compensation Committee and are intended to be a material inducement for the new employees' employment, with vesting periods of four years.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced new inducement awards for newly-hired non-executive employees, including non-qualified stock options and restricted stock units (RSUs). These grants, approved by the Compensation Committee, are intended to induce new employees to join the company, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options and RSUs will vest over four years, contingent on continuous employment.
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts
Fate Therapeutics, Inc. (NASDAQ:FATE) has received a consensus "Hold" rating from nine analysts, with an average 12-month price target of $3.92. Despite the company remaining unprofitable, institutional investors have a strong presence, owning approximately 97.54% of the stock, indicating significant hedge-fund interest. Recent financial results showed a slight beat on EPS and revenue, but analysts anticipate a full-year EPS of -1.63.
Fate Therapeutics reports positive lupus treatment data at ASH meeting
Fate Therapeutics (NASDAQ:FATE) revealed positive Phase 1 clinical data for its CAR T-cell therapy, FT819, in systemic lupus erythematosus (SLE) patients, showing significant reductions in disease activity and no dose-limiting toxicities. The company also presented preclinical data for two new CAR T-cell programs and plans for a registrational trial of FT819 in 2026. FT819's off-the-shelf nature from a clonal master induced pluripotent stem cell line is highlighted for its potential to increase patient accessibility.
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
Fate Therapeutics (NASDAQ: FATE) presented updated Phase 1 clinical data for its FT819 off-the-shelf CAR T-cell program for systemic lupus erythematosus (SLE), showing meaningful disease reduction and a favorable safety profile in twelve treated patients. The company also unveiled preclinical data for next-generation CAR T-cell programs, FT836 and FT839, for hematologic malignancies and autoimmune diseases. Fate Therapeutics plans to initiate a registrational study for FT819 in 2026, highlighting the potential for broad accessibility and efficacy of its iPSC-derived cellular immunotherapies.
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
Fate Therapeutics announced updated Phase 1 clinical data for its FT819 off-the-shelf CAR T-cell product in systemic lupus erythematosus (SLE), showing meaningful disease reduction and a favorable safety profile across 12 treated patients. The company also presented new preclinical data for next-generation CAR T-cell programs, FT836 and FT839, designed for hematologic malignancies and autoimmune diseases. These advances highlight the potential for broad, on-demand patient accessibility and preparations for a registrational study for FT819 in 2026.
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
Fate Therapeutics has released updated Phase 1 clinical data for its FT819 off-the-shelf CAR T-cell product candidate for systemic lupus erythematosus (SLE), showing meaningful disease decrease and a favorable safety profile across 12 SLE patients and one systemic sclerosis patient. The company also presented new preclinical data for next-generation CAR T-cell programs, FT836 and FT839, designed for hematologic malignancies and autoimmune diseases. These advancements highlight the potential of their iPSC-derived CAR T-cell pipeline to provide accessible and potent cell therapies.
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, announced its participation in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. Company management will engage in a fireside chat and a cell therapy panel discussion, with live and archived webcasts available on their website. The company aims to advance cutting-edge treatments for cancer and autoimmune diseases using its proprietary iPSC product platform.
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
Fate Therapeutics, Inc. announced its participation in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in New York. Company management will engage in a fireside chat and a cell therapy panel discussion. A webcast of the presentations will be available on the company's investor relations website.
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
Fate Therapeutics, Inc. (NASDAQ: FATE) announced its participation in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. Company management will engage in a fireside chat and a cell therapy panel discussion. Webcasts of these presentations will be available on the company's website.
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
Fate Therapeutics will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in New York. Company management will participate in a fireside chat and a cell therapy panel discussion. A webcast of the presentations will be available on the company's website.
Fate Therapeutics: Q3 Earnings Snapshot
Fate Therapeutics Inc. reported a loss of $32.3 million, or 27 cents per share, in its third quarter, exceeding Wall Street expectations. The clinical-stage biotech company posted revenue of $1.7 million for the period.
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) reported a Q3 loss of $0.27 per share, outperforming the Zacks Consensus Estimate of a $0.29 loss. The clinical-stage biotech company also surpassed revenue expectations, posting $1.74 million against an estimate of $0.85 million. Despite beating estimates, the company's shares have declined 37% year-to-date, and its Zacks Rank is currently a #4 (Sell).
Fate Therapeutics Receives Regulatory Authorization for International Clinical Trials of Off-the-Shelf CAR T-Cell Therapies FT819 and FT836, Expanding Patient Accessibility in Autoimmune and Oncology Indications
Fate Therapeutics (NASDAQ: FATE) has secured regulatory authorization from UK and EU bodies to activate clinical trial sites for its off-the-shelf CAR T-cell therapies, FT819 and FT836. FT819 is being evaluated for autoimmune diseases like lupus, with promising preliminary results in its Phase 1 study, showing significant reductions in disease activity. FT836 is progressing in oncology programs, targeting solid tumors without conditioning, and the company is well-capitalized to fund operations through 2027.
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
Fate Therapeutics reported its Q3 2025 financial results, highlighting advancements in its clinical programs for autoimmune diseases and solid tumors. The company received authorization in the UK and EU for its FT819 CAR T-cell therapy, which shows strong clinical activity and favorable tolerability in lupus patients. Fate Therapeutics also initiated studies for FT836 and FT839, leveraging its iPSC platform and Sword and Shield™ technology, and maintains a projected operating runway through year-end 2027 with $225.7 million in cash and investments.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. (NASDAQ: FATE) announced the grant of restricted stock units (RSUs) representing 34,700 shares to three new non-executive employees on November 1, 2025. These awards were approved by the Compensation Committee and granted under the Company’s Amended and Restated Inducement Equity Plan, aligning with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment. The RSUs will vest over four years, with 25% vesting annually, subject to continuous employment.
Needham Reiterates Fate Therapeutics (FATE) Hold Recommendation
Needham has reiterated a Hold recommendation for Fate Therapeutics (FATE) with an average one-year price target of $4.54, suggesting a 175.09% upside from its last closing price. The company's projected annual revenue is 34MM, a 302.22% increase, and institutional ownership stands at 88,591K shares, with a bullish put/call ratio of 0.09. Major shareholders include Redmile Group and Citadel Advisors.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced new employee inducement awards under Nasdaq Listing Rule 5635(c)(4). A newly-hired non-executive employee received non-qualified stock options for 60,000 shares and restricted stock units representing 45,800 shares. These grants, approved by the Compensation Committee, are designed to vest over four years.
Layoffs Continue Across Biotech Industry as More Companies Restructure and Reprioritize
The biotech industry is experiencing a continued wave of layoffs as companies like Fate Therapeutics, Generation Bio, and ORIC Pharmaceuticals restructure their operations, cut costs, and prioritize core clinical programs. This trend is driven by challenging market conditions, with firms aiming to extend their cash runways and focus on advancing lead therapies. Major players including Bayer, Merck, and Moderna have also announced significant workforce reductions recently, signaling a broader industry shift towards efficiency and strategic reprioritization.
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) reported a Q2 loss of $0.29 per share, exceeding the Zacks Consensus Estimate of a $0.35 loss, marking a 17.14% earnings surprise. The clinical-stage biotech company also surpassed revenue estimates, posting $1.91 million against a consensus of $0.65 million. Despite these positive results, FATE shares have seen a 43.3% decline year-to-date, contrasting with the S&P 500's 8.4% gain.
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
Fate Therapeutics reported its Q2 2025 financial results and business updates, highlighting progress in its FT819 CAR T-cell program for autoimmune diseases and an extended operating runway through 2027. Key developments include discussions with the FDA for FT819's registrational pathway in SLE and LN, positive interim Phase 1 SLE data, and IND allowance for FT836. The company also detailed its financial performance, showing $248.9 million in cash, cash equivalents, and investments.
Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data
H.C. Wainwright has reaffirmed its Neutral rating on Fate Therapeutics, Inc. (FATE) with a $5.00 price target, following the company's presentation of positive T819 data on lupus at the EULAR 2025 Congress. The data showed significant improvement in primary renal response for patients with lupus nephritis, highlighting the potential of its engineered cell therapy in autoimmune disease. Despite this, the firm suggests that certain AI stocks may offer greater upside potential with less downside risk.
Next-Generation Cancer Therapeutics Market Size to Hit USD 175.20 Bn by 2034
The global next-generation cancer therapeutics market is projected to grow from USD 92.54 billion in 2025 to USD 175.20 billion by 2034, driven by advancements in immunotherapy, personalized medicine, and mRNA technology, exhibiting a CAGR of 7.35%. North America currently dominates the market, while Asia Pacific is expected to achieve the fastest growth due to healthcare modernization and increased R&D. Key market drivers include the rising incidence of cancer, genomic advancements, and a favorable regulatory environment, while high pricing and taxation remain significant restraints.
Bone Degeneration Therapeutics Market Forecast: Growth
The global bone degeneration therapeutics market, valued at USD 9.2 billion in 2025, is projected to reach USD 15.9 billion by 2032, growing at a CAGR of 8.7%. This growth is driven by increasing demand and innovation. Key players include Amgen Inc. and Fate Therapeutics Inc., with the market segmented by drug type, application, and distribution channel across various regions.
Fate Therapeutics’ iPSC-derived CAR-T FT819 Nabs FDA RMAT Designation for Lupus
Fate Therapeutics' investigational iPSC-derived CAR-T therapy, FT819, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for treating active moderate to severe systemic lupus erythematosus (SLE), including lupus nephritis. The designation was based on initial clinical safety and activity data from a phase 1 trial, which showed rapid and sustained elimination of CD19+ B-cells in patients with active lupus nephritis, along with a favorable safety profile. Fate Therapeutics plans to accelerate the development of FT819, aiming to provide an off-the-shelf CAR T-cell therapy that is cost-effective and reduces patient burden.
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic
Fate Therapeutics (FATE) announced that its investigational CAR T-cell therapy, FT819, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for treating lupus. This designation allows for early FDA interactions and potential priority review, recognizing the therapy's significant potential. Despite this positive news, FATE shares fell by approximately 13% on Monday morning, with retail sentiment remaining "extremely bullish."
Fate Therapeutics Announces Leadership Transition as Bob Valamehr, Ph.D. MBA, to Succeed Scott Wolchko as President and CEO Effective January 1, 2025
Fate Therapeutics announced that Bob Valamehr, Ph.D. MBA, currently President of Research and Development, will succeed Scott Wolchko as President and CEO effective January 1, 2025. Wolchko will retire on December 31, 2024, after a decade of leading the company in iPSC-derived cellular immunotherapies. Valamehr plans to continue advancing the clinical pipeline, including the FT819 product candidate for systemic lupus erythematosus, building on the company's established leadership in off-the-shelf NK and T-cell immunotherapies.
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
Fate Therapeutics presented initial clinical and translational data for its FT522 off-the-shelf, CD19-targeted CAR NK cell product candidate at the 2024 ACR Convergence. The data from a Phase 1 study in relapsed/refractory B-cell lymphoma showed a favorable safety profile, complete responses, and persistence of FT522 live cells, especially without conditioning chemotherapy. The company is also initiating a Phase 1 basket study of FT522 for B cell-mediated autoimmune diseases, aiming to utilize its alloimmune defense receptor (ADR) technology for effective treatment without intense conditioning chemotherapy.
Fate Therapeutics Drops To US$2.81, Yet Insiders May Have Sold Too Early
Fate Therapeutics recently experienced a 13% drop in its stock price, even though insiders who sold US$190k worth of shares over the past year might have sold too early since their average selling price was higher than the current stock price of US$2.81. The article notes that insider ownership is 1.7% and no recent insider buying has occurred, suggesting insider transactions alone aren't a strong buy signal. It also highlights potential warning signs for the company.
Fate Therapeutics Announces Presentation of FT522
Fate Therapeutics announced that preclinical data for its FT522 program, targeting autoimmune diseases, will be presented at the ASGCT 27th Annual Meeting. FT522 is a CD19-targeted, iPSC-derived CAR NK cell product candidate incorporating novel alloimmune defense receptor (ADR) technology. Preclinical studies using SLE donor PBMCs demonstrated rapid B-cell depletion, enhanced functional persistence, and elimination of alloreactive host immune cells without conditioning chemotherapy.
Fate, two other cell therapy biotechs lay off staff, restructure research
Three cell therapy biotechnology companies, Fate Therapeutics, Century Therapeutics, and TCR2 Therapeutics, are implementing significant staff layoffs and restructuring research efforts. These changes are indicative of a more challenging and prolonged development path for next-generation cancer cell therapies than initially anticipated by the companies and their investors. A key factor for Fate was the termination of a partnership with Johnson & Johnson, leading to a major workforce reduction and the discontinuation of several clinical-stage programs.
The State of iPS Cell Clinical Trials in 2021
The article discusses the state of iPS cell clinical trials in 2021, highlighting the increase in trials to 54, with a few now administering iPSC-derived cellular therapeutics to human patients. It details specific trials by Cynata Therapeutics and Fate Therapeutics, as well as physician-led studies in Japan for conditions like macular degeneration, Parkinson's disease, and heart disease. The article also touches on future directions including gene editing with CRISPR-Cas9 and disease modeling.
Fate's CRISPR-edited, iPSC-derived Cell Therapy Cleared by FDA
Fate Therapeutics has announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for FT538, making it the first CRISPR-edited, iPSC-derived cell therapy worldwide to be cleared for clinical investigation. FT538 is an off-the-shelf natural killer (NK) cell cancer immunotherapy with three engineered functional components designed to enhance innate immunity. The company plans to initiate clinical investigation of FT538 in acute myeloid leukemia (AML) as a monotherapy and in combination with daratumumab for multiple myeloma (MM), and has already begun its clinical manufacture.
Fate inks $100M J&J pact for ‘off-the-shelf’ cancer cell therapies
Johnson & Johnson and Fate Therapeutics have announced a $100 million deal to co-develop allogeneic, or "off-the-shelf," cancer cell therapies. J&J will also purchase $50 million in Fate shares at a premium. This partnership aims to advance therapies for blood cancers and solid tumors, which could be more accessible and cost-effective than current autologous CAR-T treatments, despite the early stage of allogeneic research and potential COVID-19 related delays.
Fate Therapeutics Strikes Multi-Billion Dollar Cell Therapy Deal with Janssen
Fate Therapeutics has entered into a multi-billion dollar deal with Janssen Biotech to develop cell therapies for cancer, causing Fate Therapeutics' shares to rise over 21% in premarket trading. The collaboration will leverage Fate's iPSC product platform and Janssen's tumor-targeting technology to create novel CAR NK and CAR T-Cell candidates for hematologic malignancies and solid tumors, with potential payments to Fate of up to $3 billion in milestones and double-digit royalties.
J&J inks Fate deal to move into allogeneic CAR therapies
Johnson & Johnson is partnering with Fate Therapeutics in a deal worth up to $3 billion in milestones, with a $50 million upfront payment, to develop allogeneic CAR NK and CAR-T cell therapies. Fate will use its induced pluripotent stem cell (iPSC) platform for up to four targets chosen by J&J, which will fund the development and hold exclusive rights for commercialization. This collaboration expands J&J's cell therapy portfolio and provides Fate with significant funding and the option to co-commercialize in the U.S.
